Welcome to BioSeeker Group!

Triple Analysis: Lymphoma, Melanoma and Protein Kinase Inhibitors

Additional Information

Published Date Jun 12, 2013
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 5075
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Lymphoma, Melanoma and Protein Kinase Inhibitors in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in both Lymphoma and Melanoma and by the mechanism/target/effect of Protein Kinase Inhibitors.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Lymphoma, Melanoma and Protein Kinase Inhibitors.

    To find out more about Triple Analysis: Lymphoma, Melanoma and Protein Kinase Inhibitors, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Lymphoma, Melanoma and Protein Kinase Inhibitors is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in both Lymphoma and Melanoma and by the mechanism/target/effect of Protein Kinase Inhibitors. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Lymphoma
The lymphoma report part comprises defined and up to date development strategies for 282 lymphoma drugs within the portfolio of 154 investigators, from Ceased to Marketed. This part extensively analyses their 181 identified drug targets, organized into 173 drug target strategies, and assesses them in eight different compound strategies and and five subindications of lymphoma.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market

Part II: Melanoma
The melanoma drug report part comprises defined and up to date development strategies for 282 drugs within the portfolio of 164 companies world-wide, from Ceased to Marketed. The report extensively analyses their 226 identified drug targets, organized into 187 drug target strategies, and assesses them in melanoma.
This part is based on the following publication:
Melanoma Drug Development Analysis: From First-in-Class to Best-in-Class?

Part III: Protein Kinase Inhibitors
The protein kinase drug report part comprises defined and up to date development strategies for 648 drugs in oncology within the portfolio of 212 companies world-wide, from Ceased to Marketed. The report extensively analyses their 183 identified drug targets, organized into 278 drug target strategies, and assesses them in 70 cancer indications.
This part is based on the following publication:
Competitive Insights to Protein Kinase Therapeutics in Oncology: The Faster Route to Consider Your Options and Position of Others

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Lymphoma
5.1 The Scope of this Report 26
6 Consider the Therapeutic Target Among Lymphoma Drugs for the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets) 30-387
7 Emerging New Products to Established Ones: Drug Target Strategies of Lymphoma Drugs by their Highest Stage of Development (173 Drug Target Strategies and 282 Lymphoma Drugs) 388-596
8 Compound Strategies at Work: Competitive Benchmarking of Lymphoma Drugs by Compound Strategy (8 Compound Strategies) 597-636
9 Selecting Subindication for Lymphoma Drugs (Five Subindications of Lymphoma) 637-657
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Lymphoma Drug Pipeline by Investigator (152 Companies) 658-938
11 Disclaimer 939
12 Drug Index 940
13 Company Index 948
Figures: Includes 6 Figures
Tables: Includes 222 Tables
Total Number of Pages: 954

Part II: Melanoma
5.1 The Scope of this Report 26
6 Consider the Therapeutic Target Among Melanoma Drugs for the Highest Therapeutic Outcome and Return on Investment (226 Drug Targets) 30-467
7 First-in-Class and Me-too Analysis of Melanoma Drugs (187 Drug Target Strategies and 282 Drugs) 468-677
8 Is First-in-Class the Best-in-Class? 488-678
9 Compound Strategies at Work: Competitive Benchmarking of Melanoma Drugs by Compound Strategy (7 Compound Strategies) 679-710
10 The Competition Through Close Mechanistic Approximation of Melanoma Drugs 711
11 Pipeline and Portfolio Planning: Competitive Benchmarking of the Melanoma Drug Pipeline by Company (164 Companies and 282 Drugs) 716-1165
12 Disclaimer 1166
Figures: Includes 5 Figures
Tables: Includes 222 Tables
Total Number of Pages: 1,181

Part III: Protein Kinase Inhibitors
5.1 The Scope of this Report 38
6 Consider the Therapeutic Target Among Protein Kinase Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (183 Drug Targets) 42-516
7 Emerging New Products to Established Ones: Drug Target Strategies of Protein Kinase Drugs in Oncology by their Highest Stage of Development (278 Drug Target Strategies and 648 Drugs) 517-945
8 Compound Strategies at Work: Competitive Benchmarking of Protein Kinase Cancer Drugs by Compound Strategy (8 Compound Strategies) 946-1013
9 Selecting Indication for Protein Kinase Drugs in Oncology (70 Cancer Indications) 1014-1223
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Protein Kinase Drug Pipeline in Oncology by Investigator (212 Investigators and 648 Drugs) 1224-2939
11 Disclaimer 2940
Figures: Includes 8 Figures
Tables: Includes 389 Tables
Total Number of Pages: 2,940

This Report Includes the Following Companies:
3SBio
4SC
AB Science
Abbott
AbbVie
Abiogen
Acceleron Pharma
ACT Biotech
Actelion
Adherex
Advanced Life Sciences
Advaxis
Advenchen
AEgera
AEterna Zentaris
Affimed Therapeutics
Agenus
Aida Pharmaceuticals
Alethia Biotherapeutics
Alfa Wassermann
Alfacell
Allist Pharmaceuticals
Allos Therapeutics
Allostera
Alnylam
AlphaVax
Altor BioScience
Ambit Biosciences
Amgen
Amphora
AngioChem
Ansaris
Antisense Pharma
Antisoma
Aphios
Apogee Biotechnology
ApopLogic Pharmaceuticals
Apotex
Apricus Biosciences
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Ascenta Therapeutics
Astellas
Astex Pharmaceuticals
Astex Therapeutics
AstraZeneca
Attenuon
AVEO
Avila Therapeutics
Bavarian Nordic
Bayer
Benitec
Berkeley Lab
Bio-Medisinsk Innovasjon
Bio-Path Holdings
BioAlliance Pharma
BioAxone
Biocon
BioCryst Pharmaceuticals
Biogen Idec
Biokine Therapeutics
Biolex
Bionovo
BioNTech
BioNumerik
BioSante
Biosceptre
Biotech Ltd
Biotecnol
Biotica Technology
BioVex
Boehringer Ingelheim
Borean Pharma
Bristol-Myers Squibb
BTG
Callisto Pharmaceuticals
Cambrex
CanBas
Cancer Research Technology
Catalyst Biosciences
CDG Therapeutics
Celera
Celgene
Cell Therapeutics
CellCeutix
Celldex Therapeutics
Celleron
Celltrion
Celtic Pharma
Cephalon
CerRx
Chroma Therapeutics
Circadian Technologies
CJ Corp
Clavis Pharma
Cleveland BioLabs
Clinical Data
CompleGen
Compugen
CoNCERT Pharmaceuticals
Cornerstone Pharmaceuticals
Cosmo Pharmaceuticals
CSL
CureTech
Curis
Cyclacel
Cylene Pharmaceuticals
CytImmune Sciences
Cytokine PharmaSciences
Cytokinetics
Cytopia
Daewoong
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Debiopharm
Deciphera Pharmaceuticals
Dendreon
DeveloGen
DiaMedica
DNAVEC
Dong-A
Dr Reddy’s
Dyax
Dynavax Technologies
Eisai
Elara Pharmaceuticals
Eleos
Eli Lilly
Emergent BioSolutions
Enkam Pharmaceuticals
EntreMed
Enzon
EpiCept
Epizyme
Erimos
Exelixis
Favrille
Flamel Technologies
Forma Therapeutics
Galapagos
Galena Biopharma
Gemin X Biotechnologies
Genencor
Genentech
Generex
Genmab
GenPat77
Genta
GenVec
Genzyme
Geron
Gilead Sciences
GlaxoSmithKline
GlycoGenesys
GPC Biotech
Gradalis
Hanmi
Hayashibara
Heber Biotec
HemaQuest
Hemispherx Biopharma
Hoffmann-La Roche
Human Genome Sciences
Hutchison China MediTech
Hy BioPharma
Hypha Discovery
Ichor Medical Systems
Idera Pharmaceuticals
IGF Oncology
ImClone Systems
Immunocore
ImmunoFrontier
ImmunoGen
Immunomedics
Immunovaccine
ImmuPharma
Incozen Therapeutics
Incyte Corporation
Inex
Infinity Pharmaceuticals
Inhibiton Therapeutics
Innate Pharma
InNexus Biotechnology
Inotek
Inovio
Insmed
Insys Therapeutics
Intas Biopharmaceuticals
Intellikine
Intracel
Intrexon
Introgen Therapeutics
Ipsen
Isis Pharmaceuticals
ISU ABXIS
Italfarmaco
Jennerex Biotherapeutics
Jina Pharmaceuticals
Johnson & Johnson
Kadmon
KAEL-GemVax
KAI Pharmaceuticals
KaloBios
Kalypsys
Karus Therapeutics
Karyon-CTT
Keryx Biopharmaceuticals
Kiadis
Kinex
Kirin Pharma
Kissei
KuDOS
Kyowa Hakko Kirin
Leo
Lexicon Pharmaceuticals
LG Life Sciences
Ligand
Lipotek
Lorus Therapeutics
MacroGenics
Mannkind
Marina Biotech
MaxoCore Pharmaceuticals
Meda
MediGene
MedImmune
Medisyn Technologies
Merck & Co
Merck KGaA
Merrimack
MethylGene
Micromet
Mitsubishi Tanabe Pharma
Mochida
Mojave Therapeutics
Molecular LogiX
MolMed
Mologen
Myrexis
Nano Terra
Nektar Therapeutics
Nereus Pharmaceuticals
Nerviano Medical Sciences
NexusPharma
NicOx
Nidus Laboratories
NIH
Nippon Shinyaku
Non-industrial source
NovaLead
Novartis
Novogen
Noxxon
Nycomed Pharma
Oasmia
Oncalis
Onconova
OncoTherapy Science
Oncothyreon
Oncovir
OSI Pharmaceuticals
Otsuka
Oxford BioMedica
Pacific Biotech
Pathway Therapeutics
Patrys
PBL Therapeutics
Peregrine Pharmaceuticals
Pfizer
Pharmacyclics
PharmaGap
PharmaMar
Pharmexa
Philogen
PhiloGene
Phoenix Biotechnology
PHusis Therapeutics
Pieris
Pierre Fabre
Piramal
PIramed
Plexxikon
Portola Pharmaceuticals
Proacta
Progen
Progenics Pharmaceuticals
ProNAi Therapeutics
Provid
QLT
Quantum Pharmaceuticals
Ras Therapeutics
Reata Pharmaceuticals
Receptor BioLogix
Regeneron
Regulon
Reliance Life Sciences
Rexahn
Rigel
Samtheo Biopharma
Sanofi
Sanofi-Aventis
Santaris Pharma
Santhera Pharmaceuticals
Sareum
SBI Biotech
SBIO
Scancell
Schering-Plough
Seattle Genetics
Selvita
Semafore Pharmaceuticals
Sentinel Oncology
SGX Pharmaceuticals
Shire
Silence Therapeutics
Simcere Pharmaceuticals
Solbec Pharmaceuticals
Spirogen
Sunesis
SuperGen
SuppreMol
Supratek Pharma
Swedish Orphan Biovitrum
Switch Pharma
Symphogen
Synageva BioPharma
Synta Pharmaceuticals
Takeda
Tamir Biotechnology
Tapestry Pharmaceuticals
Targa Therapeutics
TargeGen
Targepeutics
Tau Therapeutics
TauTaTis
TCD Pharma
Tekmira Pharmaceuticals
Telik
TetraLogic Pharmaceuticals
Teva
Thallion Pharmaceuticals
Therion Biologics
Theryte
Tigris Pharmaceuticals
Titan Pharmaceuticals
to-BBB
Tolerx
ToolGen
TopoTarget
Tracon Pharmaceuticals
Tragara Pharmaceuticals
Transgene
TransTech Pharma
Trion Pharma
UCB
Vaccinex
VasGene Therapeutics
VBL Therapeutics
Vectura
Velacor Therapeutics
VentiRx Pharmaceuticals
Vernalis
Vertex Pharmaceuticals
Vical
Vion Pharmaceuticals
VioQuest
ViroMed
WntResearch
Wyeth
XBiotech
Xcovery
Xencor
Xerion
Yakult Honsha
YM BioSciences
York Pharma
Zenotech
Zenyaku Kogyo
A Shortlist of Drugs Included are:
131I-tositumomab
AC-480
AE-37
AEB071
AF-802
afatinib
agatolimod
aldesleukin
alemtuzumab
ALT-801
alvocidib
AMG-386
amrubicin hydrochloride
Angiozyme
apatinib
APO-866
AR-42
ARQ-197
ARRY-438162
astuprotimut-r
AT-7519
AT-9283
Auto TAG vaccine
axitinib
AZD-8055
AZD-8931
bafetinib
barasertib
bardoxolone methyl
belinostat
bevacizumab
bexarotene
BEZ-235
BGT-226
BI-811283
BIBF-1120
BMS-663513
BMS-690514
BMS-754807
BMS-777607
BMS-936558
bortezomib
bosutinib
brentuximab vedotin
brivanib alaninate
Buparlisib
Cabozantinib
CAL-101
CB-10-01
CBP-501
CC-223
cediranib
cilengitide
cladribine
cositecan
crizotinib
CT-011
dacomitinib
danusertib
dasatinib
decitabine
denenicokin
denileukin diftitox
dinaciclib
dovitinib lactate
E-75
E7449
elliptinium acetate
EMD-273063
endostatin
endoxifen
ENMD-2076
entinostat
enzastaurin hydrochloride
epirubicin
erlotinib
everolimus
Exherin
foretinib
fostamatinib disodium
fresolimumab
galiximab
ganetespib
ganitumab
gefitinib
glembatumumab vedotin
golvatinib
GSK-1120212
GSK-2118436
GV-1001
GVAX
HBP-347
Hi-8 MEL
histamine dihydrochloride
ibritumomab tiuxetan
IC-83
icrucumab
idronoxil
imatinib mesilate
INCB-028060
INCB-24360
inotuzumab ozogamicin
INSM-18
interferon
interferon (alpha)
interferon (alpha2b)
interferon (gamma)
interferon alfa-2b
interferon alpha-2b
interleukin-12
interleukin-2
intetumumab
IPH-1101
ipilimumab
irinotecan hydrochloride
ispinesib mesylate
JI-101
JX-594
kahalalide F
KD032
KX2-391
L19-IL2
Lambrolizumab
lapatinib ditosylate
LEE-011
lenvatinib
lestaurtinib
LGX818
linifanib
linsitinib
LipoVIL12
LY-2090314
masitinib
MDX-1379
MetXia
MGCD-265
MGN-1601
midostaurin
mitoxantrone
MK-1775
MKC-1
MKC-1106-MT
MLN-8237
MM-111
MORAb-004
motesanib diphosphate
MVA-BN Her-2 vaccine
neratinib
nilotinib
NPB-001-056
obinutuzumab
oblimersen sodium
ofatumumab
ON-01910
onartuzumab
OncoVAX
OSI-027
OTS-102
P276-00
panobinostat
pazopanib hydrochloride
PD-0332991
pegdinetanib
peginterferon alfa-2b
perifosine
PHA-848125AC
pimasertib
pixantrone
plitidepsin
poly-ICLC
ponatinib
pralatrexate
PX-866
quinacrine
quizartinib dihydrochloride
RAF-265
ramucirumab
razoxane
Reditux
regorafenib
retaspimycin
rhIFN-alpha
ridaforolimus
rilotumumab
rintatolimod
rituximab
romidepsin
ruxolitinib
RX-0201-N
sagopilone
sargramostim
SCH-900776
SCIB-1
seliciclib
selumetinib
sirolimus
sobuzoxane
sorafenib tosylate
ß-lapachone
SU-6668
sunitinib malate
talmapimod
talminogene laherparepvec
tandutinib
telatinib
temsirolimus
teniposide
terameprocol
tesetaxel
thalidomide
thymalfasin
tivozanib
trabedersen
tremelimumab
triciribine phosphate
vandetanib
varlitinib
velimogene aliplasmid
veliparib
vemurafenib
verubulin
vinflunine ditartrate
vitespen
volasertib
volociximab
vosaroxin
XL-147
XL-281
XL-413
XL-647
XL-765
YM-155
zanolimumab

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Lymphoma, Melanoma and Protein Kinase Inhibitors.
    To find out more about Triple Analysis: Lymphoma, Melanoma and Protein Kinase Inhibitors, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Lymphoma, Melanoma and Protein Kinase Inhibitors is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Breast Cancer, Lymphoma and Melanoma
This triple analysis focuses on cancer drug development strategies in Breast Cancer, Lymphoma and Melanoma. Learn More


Triple Analysis: Colorectal Cancer, Apoptosis and Antibodies
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Colorectal Cancer), one mechanism/target/effect area (Apoptosis) and one compound specific area (Antibodies). Learn More

Other selected research from the 'Oncology' category:


Competitive Insights to Protein Kinase Therapeutics in Oncology: The Faster Route to Consider Your Options and Position of Others
This report represents a new and unique way of stratifying and analyzing the global protein kinase drug pipeline in oncology towards personalized medicine. Learn More


A Decision Support Tool for Optimizing the Melanoma Pipeline: From Research and Development to Market
This report comprises defined and up to date development strategies for 218 melanoma drugs within the portfolio of 138 companies, from Ceased to Marketed. The report extensively analyses their 170 identified drug targets, organized into 151 drug target strategies, and assesses them in eight different compound strategies in melanoma. Learn More